相关实验视频

Updated: Jun 28, 2025

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

Published on: January 29, 2017

药物坚持治疗的试点随机对照试验:使用显著其他 (MAT-PLUS) 的心理社会杆,用于延长释放纳尔德的人

Kevin Wenzel¹, Julia Thomas¹, Jennifer Carrano¹

¹Maryland Treatment Centers, 3800 Frederick Ave, Baltimore, MD 21229, United States of America.

Journal of substance use and addiction treatment

|April 18, 2024

概括

MAT-PLUS干预显著改善了对阿片类药物使用障碍 (OUD) 和酒精使用障碍 (AUD) 的延长释放纳尔德 (XR-NTX) 的坚持. 这种方法涉及积极的外展和家庭支持,有望提高成治疗的保留率.

科学领域:

成药物药物药物药物
临床心理学临床心理学
药理学药理学是指药理学的学科.

背景情况:

延长释放纳尔德 (XR-NTX) 是对阿片类药物使用障碍 (OUD) 和酒精使用障碍 (AUD) 的关键治疗方法.
不良的患者保留和坚持显著限制了XR-NTX的有效性.
在成治疗中,急需进行干预措施,以提高药物坚持度.

研究的目的:

试点测试MAT-PLUS干预措施,旨在提高对XR-NTX的坚持.
评估积极的外展和治疗的综合效应其他重大 (TSO) 参与.

主要方法:

一项随机对照试验涉及41名OUD/AUD成年人接受XR-NTX.
参与者被分配到MAT-PLUS干预或通常的治疗 (TAU) 中,持续16周.
主要结局是接收的XR-NTX剂量数量;复发是次要结局.

主要成果:

与TAU相比,MAT-PLUS组获得的XR-NTX剂量 (3.4比2.5,p<0.05) 显著更多.
在MAT-PLUS组中,药物坚持率更高 (61.1%对30.4%),治疗所需数 (NNT) 为3.3.
两组之间没有观察到复发率或大量使用日数的显著差异.

结论:

该MAT-PLUS干预措施在改善XR-NTX粘附方面表现出初步的有效性.
家庭支持,专注于药物坚持,具有改善成治疗结果的巨大潜力.
未来的研究应该探索MAT-PLUS在更大的人群中使用物质使用障碍的不同药物的更广泛应用.

关键词:

酒精使用障碍饮酒障碍坚定的外展积极的外展家庭参与家庭参与药物治疗的坚持药物治疗的坚持药物辅助治疗是一种药物辅助治疗.片类药物使用障碍治疗其他显著的其他.

更多相关视频

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers

Published on: January 5, 2018

相关概念视频

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...